BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $70.00 price objective on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 152.34% from the stock’s current price. BBIO has […]
Primecap Management Co. CA boosted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 0.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 944,000 shares of the company’s stock after acquiring an additional 5,300 shares during the quarter. Primecap Management […]
Primecap Management Co. CA lifted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 944,000 shares of the company’s stock after acquiring an additional 5,300 shares during the period. Primecap […]
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) and Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability. Valuation & Earnings This table compares BridgeBio […]